Weslaco ISD staff recommend renewing insurance contracts; trustees briefed on $1M claims budget pressure

WESLACO — Superintendent Richard Rivera and risk management staff recommended that the Weslaco ISD Board include several insurance renewals on the consent agenda after a workshop discussion on plan performance and projected costs.

The renewals would keep Blue Cross Blue Shield as the district’s health and pharmacy administrator, MetLife for dental, TriStar as the third‑party administrator for self‑funded workers’ compensation, and Miracle Medical for diabetes testing supplies. Staff said those renewals reflect months of negotiating and a mix of RFP results and BAFOs (best and final offers).

Why it matters: The district is self‑funded for medical claims, so administrative fees and pharmacy rebates affect the budget differently than doctors’ claim payments. Rivera said the district is budgeting an approximately $1,000,000 increase for next year to cover expected higher claim costs rather than administrative fees.

District recommendations and key numbers came from risk management and external consultants. On diabetes testing supplies, staff reported Miracle Medical lowered the price for testing strips back to the prior level ($35 for testing strips and $10 for lancets, per staff presentation) and removed a tariff pass‑through clause after negotiation. For workers’ compensation, TriStar offered a negotiated three‑year fixed fee of $72,500, down from an initial $85,000 bid.

On property and fleet/liability coverage the district presented two package options: remain with Liberty Mutual at about $440,000 (roughly $73,000 more than current premiums, including a misconduct liability rider), or move to a carrier identified in the presentation as "Texas political subdivision" for about $361,000 with separate procurement of misconduct liability. Staff recommended the lower‑cost option.

On dental, staff recommended renewing the third and final year of the current MetLife agreement; initial renewal quotes were higher but negotiations cut the proposed increase to roughly 4 percent, which the district expects to absorb with an employee‑only base plan increase of about $0.33 per month. Staff said the district will put the dental plan out to RFP at the end of the 2025–26 school year.

The largest discussion focused on medical and pharmacy: risk management said Blue Cross Blue Shield’s administrative fees rose only modestly (the administrator fee rose about $1.11 while the prescription drug rebate credit rose about $4.20 per subscriber, producing a net administrative advantage). The district reported guaranteed pharmacy rebate credits that lower net administrative costs and already produced a sizeable passthrough this year — staff cited a roughly $890,000 “true‑up” in February plus guaranteed administrative passthroughs that totaled in the high six figures. Risk management estimated the combined rebate and passthrough benefit at roughly $1.1–$1.8 million received against claims and administrative costs this year.

On pharmacy utilization and high‑cost specialty drugs: trustees asked about diabetes weight‑loss medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — and whether the plan would restrict access. Sean Cope, a consultant with 1Digital, said the plan uses step‑therapy and prior authorization for new starts; patients already on those medications with prior approvals would remain covered. "Those that really needed [them] had already been preapproved," Cope said. Trustee discussion requested a later, de‑identified utilization breakdown by class of drug so board members could judge scale and budget impact.

Blue Cross Blue Shield representative Tita Iruegas answered network questions: "We do have MD Anderson in our network. It's only the Medicare [relationship]," she said, clarifying that for active, non‑Medicare employees MD Anderson is in the network for non‑Medicare coverage.

Staff emphasized the district’s objective for its self‑insured program: to be financially neutral. "The name of the game is 0 net," Rivera said, summarizing the office’s goal to neither over‑charge employees nor end the year with a large surplus from benefit contributions.

What the board did or directed: Staff recommended all renewals be placed on the consent agenda for the regular meeting; the board did not take a final vote on benefits during the workshop but heard the recommendations and asked for follow‑up materials, including utilization breakdowns for high‑cost drugs and clarification of rebate mechanics.

Ending note: Risk management asked trustees to expect a modest employee contribution increase on the employee‑only medical tier (presented estimates ranged from about $2.48 monthly in one slide to $2.48–$3.00 per month depending on final rounding) and said staff will return with final premium figures and the specific language for consent items prior to the final vote.